Tyrosine Kinase Signaling in Cancer Cell Metabolism
Tyrosine Kinase Signaling in Cancer Cell Metabolism
批准号:
7889069
负责人:
Jing Chen
金额:
$32.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-23 至 2014-12-31
关键词:
8p11AcuteAdultAttenuatedBindingBiological AssayCancer ModelCell LineCell ProliferationCell Surface ReceptorsCellsCytoplasmic TailDependenceDevelopmentDisease ProgressionEnzymesEpidermal Growth Factor ReceptorFGFR1 geneGlucoseGlycolysisH1299HumanHypoxiaIn VitroMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMediatingMetabolicMetabolic PathwayMetabolismMolecularMusMyeloproliferative diseaseNormal tissue morphologyOncogenicOxidative PhosphorylationOxygenPDH kinasePathogenesisPathway interactionsPhosphorylationPhosphotransferasesProductionProliferatingProtein IsoformsProtein Tyrosine KinaseProteinsProteomicsPyruvate KinaseRNA InterferenceRegulationReportingRoleSignal TransductionStem cellsTestingTyrosineTyrosine PhosphorylationTyrosine Phosphorylation SiteWarburg EffectWorkaerobic glycolysisbasecancer cellcofactorenzyme activityfetalglucose metabolismin vivoinsightlactate dehydrogenase Aleukemiamutantneoplastic celloverexpressionprogramspublic health relevancereceptortumortumor growthtumorigenesis
中文摘要
描述(由申请人提供):Warburg效应描述了一种促癌代谢开关,癌细胞比正常组织吸收更多的葡萄糖,但使用更少的葡萄糖进行氧化磷酸化,即使在氧气存在的情况下也有利于糖酵解。然而,这对人类癌症的发病机制和疾病进展有多重要仍不清楚。我们通过检查酪氨酸激酶信号是否调节Warburg效应,从而促进肿瘤的发生和维持来解决这些问题。酪氨酸激酶信号在肿瘤中通常上调。这一假设建立在我们的观察基础上,即在表达FGFR1融合酪氨酸激酶的白血病细胞中,糖酵解和氧化磷酸化的一系列关键蛋白效应物受到酪氨酸磷酸化的调节,而酪氨酸激酶与8p11干细胞骨髓增殖性疾病(MPD)有关。这些蛋白因子包括丙酮酸激酶M2(胎儿)异构体(PKM2)、乳酸脱氢酶A (LDH-A)和丙酮酸脱氢酶激酶1 (PDHK1),它们共同作用,紧密调节细胞中的代谢途径。因此,我们的总体假设是,致癌的FGFR1通过PKM2、PDHK1和LDH-A的磷酸化,以急性方式重编程癌细胞代谢,从而促进Warburg效应和肿瘤发生。在本提案中,我们将使用表达活性FGFR1融合酪氨酸激酶的致癌基因FGFR1相关的8p11 MPD和肺癌过表达FGFR1作为平台。提出了三个具体目标:(1)阐明FGFR1通过直接磷酸化PKM2、PDHK1和LDH-A重编程癌细胞代谢的分子机制;(2)确定fgfr1介导的PKM2、PDHK1和LDH-A磷酸化是否促进了癌细胞中氧化磷酸化向有氧糖酵解的代谢转换;(3)确定fgfr1介导的PKM2、PDHK1和LDH-A磷酸化是否对肿瘤细胞增殖和肿瘤发展具有代谢优势。我们将在小鼠癌症模型中测试上述“拯救”细胞系对糖酵解增殖的依赖性和形成肿瘤的能力。
英文摘要
DESCRIPTION (provided by applicant): The Warburg effect describes a pro-oncogenic metabolism switch that cancer cells take up more glucose than normal tissue, yet use less glucose for oxidative phosphorylation and favor glycolysis even in the presence of oxygen. However, how crucial this is for pathogenesis and disease progression in human cancers remains unknown. We approached these questions by examining whether tyrosine kinase signaling - commonly upregulated in tumors - regulates the Warburg effect to contribute to tumorigenesis and maintenance of the tumor. This hypothesis builds on our observation that a spectrum of key protein effectors of glycolysis and oxidative phosphorylation are regulated by tyrosine phosphorylation in leukemia cells expressing FGFR1 fusion tyrosine kinases, which are associated with 8p11 stem cell myeloproliferative disorder (MPD). These protein factors include pyruvate kinase M2 (fetal) isoform (PKM2), lactate dehydrogenase A (LDH-A), and pyruvate dehydrogenase kinase 1 (PDHK1), which work together to tightly regulate the metabolic pathways in cells. Thus, our overall hypothesis is that oncogenic FGFR1 promotes the Warburg effect and tumorigenesis by reprogramming cancer cell metabolism in an acute way via phosphorylation of PKM2, PDHK1 and LDH-A. In this proposal, we will use oncogenic FGFR1-associated 8p11 MPD expressing active FGFR1 fusion tyrosine kinases and lung cancer overexpressing FGFR1 as platforms. Three Specific Aims are proposed: (1) To elucidate the molecular mechanisms by which FGFR1 reprograms cancer cell metabolism through direct phosphorylation of PKM2, PDHK1 and LDH-A; (2) To determine whether FGFR1-mediated phosphorylation of PKM2, PDHK1 and LDH-A promotes the metabolic switch to aerobic glycolysis from oxidative phosphorylation in cancer cells; (3) To determine whether FGFR1-mediated phosphorylation of PKM2, PDHK1 and LDH-A provides a metabolic advantage to tumor cell proliferation and tumor development. We will test the aforementioned "rescue" cell lines for dependence on glycolysis to proliferate and ability to form tumors in murine models of cancer.
PUBLIC HEALTH RELEVANCE: The Warburg effect describes a pro-oncogenic metabolism switch that cancer cells take up more glucose than normal tissue, yet use less glucose for oxidative phosphorylation and favor glycolysis even in the presence of oxygen. However, how crucial this is for pathogenesis and disease progression in human cancers remains unknown. Our overall hypothesis is that oncogenic FGFR1 programs cancer cell metabolism through tyrosine phosphorylation of metabolic enzymes including PKM2, PDHK1 and LDH-A to promote the Warburg effect and tumor growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of EMT transcription factor Zeb2 in fetal hematopoiesis
-
批准号:10604587
-
项目类别:
-
资助金额:$3.36万
-
财政年份:2023
-
负责人:Jing Chen
-
依托单位:
Dietary trans-vaccenic acid enhances anti-tumor immunity
-
批准号:10562449
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2022
-
负责人:Jing Chen
-
依托单位:
Oxidative pentose phosphate pathway regulates AMPK
-
批准号:10381359
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2021
-
负责人:Jing Chen
-
依托单位:
Mathematical modeling of spatiotemporal and mechanical processes in cellular functions
-
批准号:10028816
-
项目类别:
-
资助金额:$37.32万
-
财政年份:2020
-
负责人:Jing Chen
-
依托单位:
Mathematical modeling of spatiotemporal and mechanical processes in cellular functions
-
批准号:10471262
-
项目类别:
-
资助金额:$37.17万
-
财政年份:2020
-
负责人:Jing Chen
-
依托单位:
Mathematical modeling of spatiotemporal and mechanical processes in cellular functions
-
批准号:10237345
-
项目类别:
-
资助金额:$37.08万
-
财政年份:2020
-
负责人:Jing Chen
-
依托单位:
Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A
-
批准号:10305369
-
项目类别:
-
资助金额:$40.83万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Signaling and Targeting of 6-Phosphogluconate Dehydrogenase in Human Cancers
-
批准号:9000567
-
项目类别:
-
资助金额:$32.54万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A
-
批准号:10580662
-
项目类别:
-
资助金额:$38.56万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A
-
批准号:10524081
-
项目类别:
-
资助金额:$6.22万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Signaling and Targeting of 6-Phosphogluconate Dehydrogenase in Human Cancers
-
批准号:8630691
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Signaling and Targeting of 6-Phosphogluconate Dehydrogenase in Human Cancers
-
批准号:8838743
-
项目类别:
-
资助金额:$32.96万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Mitochondrial acetyl-CoA acetyltransferase 1 promotes the Warburg effect
-
批准号:8807929
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Mitochondrial acetyl-CoA acetyltransferase 1 promotes the Warburg effect
-
批准号:9212121
-
项目类别:
-
资助金额:$32.51万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A
-
批准号:10738318
-
项目类别:
-
资助金额:$1.55万
-
财政年份:2014
-
负责人:Jing Chen
-
依托单位:
Signaling importance of ‘functionless’ lyso-PAF, an inactive form of platelet activating factor, in melanoma with mutant Nras
-
批准号:10570178
-
项目类别:
-
资助金额:$40.58万
-
财政年份:2010
-
负责人:Jing Chen
-
依托单位:
Tyrosine Kinase Signaling in Cancer Cell Metabolism
-
批准号:8212152
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2010
-
负责人:Jing Chen
-
依托单位:
Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling
-
批准号:10303685
-
项目类别:
-
资助金额:$15.7万
-
财政年份:2010
-
负责人:Jing Chen
-
依托单位:
Tyrosine Kinase Signaling in Cancer Cell Metabolism
-
批准号:8588902
-
项目类别:
-
资助金额:$30.5万
-
财政年份:2010
-
负责人:Jing Chen
-
依托单位:
Tyrosine Kinase Signaling in Cancer Cell Metabolism
-
批准号:8033719
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2010
-
负责人:Jing Chen
-
依托单位:
海外基金